Get Our Top Trade Ideas Delivered Daily - 65% Off Now

+ New Watchlist

Benzinga Research

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

CRISPR Therapeutics

CRSPNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$49.49

0.110.22%

At close: Sep 19, 7:19 PM EDT

$49.60

0.110.22%

After Hours: 7:19 PM EDT

15 minutes delayed

CRISPR Therapeutics (CRSP) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics Stock (NASDAQ: CRSP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, August 12, 2024

Truist Securities Maintains Buy on CRISPR The...
Benzinga Newsdesk

Thursday, August 08, 2024

Cantor Fitzgerald Reiterates Neutral on CRISP...
Benzinga Newsdesk
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Avi Kapoor

Tuesday, August 06, 2024

Barclays Maintains Equal-Weight on CRISPR The...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on CRISP...
Benzinga Newsdesk
Stifel Maintains Hold on CRISPR Therapeutics,...
Benzinga Newsdesk
Chardan Capital Maintains Buy on CRISPR Thera...
Benzinga Newsdesk
Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk

Monday, August 05, 2024

CRISPR Therapeutics Q2 2024 Adj EPS $(1.49) B...
Benzinga Newsdesk

Thursday, July 11, 2024

Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
Benzinga Neuro

Friday, June 28, 2024

Guggenheim Assumes CRISPR Therapeutics at Neu...
Benzinga Newsdesk

Thursday, June 27, 2024

Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk

Tuesday, June 25, 2024

Intellia Therapeutics Presents Data On Redosi...
Benzinga Newsdesk

Monday, June 17, 2024

Piper Sandler Reiterates Overweight on CRISPR...
Benzinga Newsdesk
Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk

Thursday, May 23, 2024

Citigroup Maintains Buy on CRISPR Therapeutic...
Benzinga Newsdesk
CRISPR Therapeutics' Julianne Bruno, M.B.A., ...
Benzinga Newsdesk

Friday, May 10, 2024

Oppenheimer Maintains Outperform on CRISPR Th...
Benzinga Newsdesk

Thursday, May 09, 2024

JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on CRISPR ...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Neutral on CRISP...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on CRISPR The...
Benzinga Newsdesk
Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk
Baird Maintains Neutral on CRISPR Therapeutic...
Benzinga Newsdesk

Wednesday, May 08, 2024

CRISPR Therapeutics Q1 EPS $(1.43) Misses $(1...
Benzinga Newsdesk

Thursday, April 18, 2024

Citigroup Maintains Buy on CRISPR Therapeutic...
Benzinga Newsdesk

Wednesday, April 17, 2024

CRISPR Therapeutics's Options Frenzy: What You Need to Know
Benzinga Insights

Thursday, April 11, 2024

Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk

Thursday, March 21, 2024

Smart Money Is Betting Big In CRSP Options
Benzinga Insights

Tuesday, March 19, 2024

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Benzinga Insights

Wednesday, March 13, 2024

Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
Benzinga Neuro

Wednesday, March 06, 2024

Mizuho Maintains Buy on CRISPR Therapeutics, ...
Benzinga Newsdesk

Monday, March 04, 2024

Smart Money Is Betting Big In CRSP Options
Benzinga Insights

Monday, February 26, 2024

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Vandana Singh
Morgan Stanley Maintains Underweight on CRISP...
Benzinga Newsdesk

Friday, February 23, 2024

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Benzinga Insights

Thursday, February 22, 2024

Smart Money Is Betting Big In CRSP Options
Benzinga Insights
RBC Capital Maintains Sector Perform on CRISP...
Benzinga Newsdesk
CRISPR Therapeutics shares are trading higher...
Benzinga Newsdesk
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
Chardan Capital Maintains Buy on CRISPR Thera...
Benzinga Newsdesk

Wednesday, February 21, 2024

Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk
CRISPR Therapeutics Q4 EPS $1.10 Vs $(1.41) Y...
Benzinga Newsdesk

Thursday, February 15, 2024

What's Going On With Crispr Therapeutics Stock?
Erica Kollmann
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Wolfe Research Initiates Coverage On CRISPR T...
Benzinga Newsdesk

Wednesday, February 14, 2024

Check Out What Whales Are Doing With CRSP
Benzinga Insights

Tuesday, February 13, 2024

CRISPR Therapeutics Announces $280M Registere...
Benzinga Newsdesk
European Commission Approves First CRISPR/Cas...
Benzinga Newsdesk

Friday, February 09, 2024

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Benzinga Insights

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved